Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.

Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K, Hilger RA, Scheulen ME, Christensen O, Brendel E, Schwartz B, Hofstra E, Voigtmann R, Seeber S, Strumberg D.

Clin Colorectal Cancer. 2005 Sep;5(3):188-96.

PMID:
16197622
2.

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B.

Oncologist. 2007 Apr;12(4):426-37. Review.

3.

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S.

J Clin Oncol. 2005 Feb 10;23(5):965-72. Epub 2004 Dec 21.

PMID:
15613696
4.

Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.

Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.

J Clin Oncol. 2009 Sep 1;27(25):4169-76. doi: 10.1200/JCO.2008.18.8193. Epub 2009 Jul 27.

PMID:
19636022
5.

UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors.

Sastre J, Aranda E, Abad A, Gallego J, Manzano JL, Gómez A, Carrato A, López E, Díaz-Rubio E; TTD Group.

Anticancer Drugs. 2006 Apr;17(4):417-21.

PMID:
16549999
6.

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Keating GM, Santoro A.

Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. Review.

PMID:
19228077
7.

A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.

Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE.

Cancer. 2011 Sep 15;117(18):4194-200. doi: 10.1002/cncr.25931. Epub 2011 Mar 8.

8.

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.

Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Giannaris T, Lathia C, Petrenciuc O, Moore MJ.

Clin Cancer Res. 2006 Jan 1;12(1):144-51.

9.

Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.

Hütter G, Szélenyi H, Deckert PM, Keilholz U, Thiel E.

Cancer Chemother Pharmacol. 2004 Aug;54(2):178-84. Epub 2004 Apr 28.

PMID:
15114411
10.

Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.

Hanauske AR, Cassidy J, Sastre J, Bolling C, Jones RJ, Rakhit A, Fettner S, Brennscheidt U, Feyereislova A, Díaz-Rubio E.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):523-31.

11.

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T.

Eur J Cancer. 2012 Mar;48(4):465-74. doi: 10.1016/j.ejca.2011.12.026. Epub 2012 Jan 27.

PMID:
22285181
13.

A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer.

Kim HS, Park MJ, Uhm JE, Lee Y, Lee HY, Kang EM, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS.

Int J Colorectal Dis. 2009 Nov;24(11):1311-6. doi: 10.1007/s00384-009-0758-3. Epub 2009 Jul 17.

PMID:
19609538
14.

Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.

Duran I, Hotté SJ, Hirte H, Chen EX, MacLean M, Turner S, Duan L, Pond GR, Lathia C, Walsh S, Wright JJ, Dancey J, Siu LL.

Clin Cancer Res. 2007 Aug 15;13(16):4849-57.

15.

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.

Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K.

Cancer Sci. 2008 Jul;99(7):1492-8. doi: 10.1111/j.1349-7006.2008.00837.x. Epub 2008 May 12.

16.

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M.

J Clin Oncol. 2009 Sep 10;27(26):4274-80. doi: 10.1200/JCO.2009.22.0541. Epub 2009 Aug 3.

PMID:
19652055
17.

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.

Pölcher M, Eckhardt M, Coch C, Wolfgarten M, Kübler K, Hartmann G, Kuhn W, Rudlowski C.

Cancer Chemother Pharmacol. 2010 May;66(1):203-7. doi: 10.1007/s00280-010-1276-2. Epub 2010 Mar 5.

PMID:
20204367
18.

Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.

Simonelli M, Zucali PA, Lorenzi E, Rubino L, De Vincenzo F, De Sanctis R, Perrino M, Mancini L, Di Tommaso L, Rimassa L, Masci G, Zuradelli M, Suter MB, Bertossi M, Fattuzzo G, Giordano L, Roncalli MG, Santoro A.

Eur J Cancer. 2013 Mar;49(5):989-98. doi: 10.1016/j.ejca.2012.10.016. Epub 2012 Nov 9.

PMID:
23146956
19.

Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.

Takimoto CH, Awada A.

Cancer Chemother Pharmacol. 2008 Apr;61(4):535-48. Epub 2007 Nov 17. Review.

PMID:
18026728
20.

Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.

Schultheis B, Kummer G, Zeth M, Brendel E, Xia C, Kornacker M, Strumberg D.

Cancer Chemother Pharmacol. 2012 Feb;69(2):333-9. doi: 10.1007/s00280-011-1685-x. Epub 2011 Jul 8.

PMID:
21735354

Supplemental Content

Support Center